Miromatrix Medical Inc

Miromatrix Medical, Inc. operates as a biotechnology company, which engages in the development of biological human organs to solve the chronic shortage of transplantable organs. It offers perfusion decellularization and recellularization technology, as well as organ-derived biological products such as MIROMESH and MIRODERM for soft tissue reinforcement and advanced wound care. The company was founded in 2009 by Doris A. Taylor and Cohen Robert and is headquartered in Eden Prairie, MN.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EDEN PRAIRIE, Minn., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced its participation in the H.C. Wainwright Annual Global Investment Conference on September 11th, 2023.

Miromatrix Announces Participation in H.C. Wainwright Global Investment Conference

EDEN PRAIRIE, Minn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced its participation in the upcoming Alliance for Regenerative Medicine (ARM) Tissue Engineering and Therapeutics Workshop held on September 6, 2023.

Miromatrix Announces Participation in the ARM Tissue Engineering and Therapeutics Workshop

Miromatrix Medical Inc. (NASDAQ:MIRO ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Max Forgan - Gilmartin Investor Relations Jeff Ross - Chief Executive Officer Jim Douglas - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Phillip Dantoin - Piper Sandler Operator Good day, and welcome to the Miromatrix Medical, Inc. Second Quarter 2023 Earnings Conference Call. All participants' will be in listen-only mode.

Miromatrix Medical Inc. (MIRO) Q2 2023 Earnings Call Transcript

EDEN PRAIRIE, Minn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported second quarter 2023 financial results and provided a corporate update.

Miromatrix Reports Second Quarter 2023 Results and Provides Corporate Update

EDEN PRAIRIE, Minn., July 25, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the second quarter 2023 after market close on Monday, August 14, 2023. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time.

Miromatrix to Report Second Quarter 2023 Financial Results

EDEN PRAIRIE, Minn., July 13, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced that its poster entitled Initial Preclinical Evaluation of a Bioengineered Kidney was selected Best in Congress at the recent American Transplant Congress (ATC).

Miromatrix Poster Voted Best in Congress at the 2023 American Transplant Congress; Jack Lake Wins Lifetime Achievement Award

EDEN PRAIRIE, Minn., June 01, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that Miromatrix and John Barry have mutually agreed to end his employment as Vice President of Research and Development ("R&D") effective on or around June 13, 2023, and that Jeff Ross, Ph.D., Chief Executive Officer, will assume leadership responsibilities for the R&D organization.

Miromatrix Announces CEO Jeff Ross, Ph.D. will Expand His Role by Resuming Leadership of R&D

EDEN PRAIRIE, Minn., May 30, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced it will be presenting at the upcoming 2023 American Transplant Congress ("ATC") held on June 3rd to June 7th, 2023 in San Diego, California.

Miromatrix Presenting at the 2023 American Transplant Congress

EDEN PRAIRIE, Minn., May 30, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced that members of the management team will participate in the upcoming 20th Annual Craig-Hallum Institutional Investor Conference on May 31st, 2023. Due to the format of this event, no webcast will be available.

Miromatrix Announces Participation in the 20th Annual Craig-Hallum Institutional Investor Conference

Miromatrix Medical Inc. (NASDAQ:MIRO ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Hannah Jeffrey - Gilmartin, Investor Relations Jeff Ross - Chief Executive Officer Jim Douglas - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Operator Greetings and welcome to the Miromatrix Medical, Inc. First Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Miromatrix Medical Inc. (MIRO) Q1 2023 Earnings Call Transcript

Miromatrix Medical Inc. (MIRO) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.35 per share a year ago.

Miromatrix Medical Inc. (MIRO) Reports Q1 Loss, Misses Revenue Estimates

EDEN PRAIRIE, Minn., May 11, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported first quarter 2023 financial results and provided a corporate update.

Miromatrix Reports First Quarter 2023 Results and Provides Corporate Update

EDEN PRAIRIE, Minn., April 27, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the first quarter 2023 after market close on Thursday, May 11, 2023. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time.

Miromatrix to Report First Quarter 2023 Financial Results

EDEN PRAIRIE, Minn., April 10, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced that CEO Jeff Ross, Ph.D will present at the 2023 Cell & Gene Meeting on the Mediterranean. The conference will be held April 12 – 14 in Barcelona, Spain, bringing together leading public and private sector cell and gene therapy companies.

Miromatrix CEO Jeff Ross to Present at the 2023 Cell & Gene Meeting on the Med

CareDx

BRISBANE, Calif. & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) and Miromatrix Medical Inc. (“Miromatrix”) (Nasdaq: MIRO) – today announced an exclusive partnership aimed at advancing the next wave of innovation using fully transplantable human bioengineered organs.

CareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation

Miromatrix Medical Inc. (NASDAQ:MIRO ) Q4 2022 Earnings Conference Call March 31, 2023 4:30 PM ET Company Participants Hannah Jeffrey - Investor Relations Jeff Ross - Chief Executive Officer Jim Douglas - Chief Financial Officer Conference Call Participants Phillip Dantoin - Piper Sandler Alex Nowak - Craig-Hallum Capital Group Operator Greetings and welcome to the Miromatrix Medical, Inc. Fourth Quarter and Full Year 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Miromatrix Medical Inc. (MIRO) Q4 2022 Earnings Call Transcript

Miromatrix Medical Inc. (MIRO) delivered earnings and revenue surprises of 10.81% and 9,200%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Miromatrix Medical Inc. (MIRO) Reports Q4 Loss, Tops Revenue Estimates

EDEN PRAIRIE, Minn., March 31, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported fourth quarter and full year 2022 financial results and provided a corporate update.

Miromatrix Reports Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

EDEN PRAIRIE, Minn., March 15, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the fourth quarter and full year 2022 after market close on Friday, March 31, 2023. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time.

Miromatrix to Report Fourth Quarter and Full Year 2022 Financial Results

Miromatrix Medical (NASDAQ: MIRO ) stock is falling on Wednesday after the life sciences company priced shares for a public offering. That public offering has Miromatrix Medical selling 6,250,000 shares of MIRO stock for a price of $1.60 each.

Why Is Miromatrix Medical (MIRO) Stock Down 41% Today?

EDEN PRAIRIE, Minn., March 07, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (“Miromatrix”) (Nasdaq: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $1.60 per share, before underwriting discounts and commissions. The gross proceeds to Miromatrix from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Miromatrix are expected to be $10.0 million. The offering is expected to close on March 10, 2023, subject to customary closing conditions. Additionally, Miromatrix has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering will be sold by Miromatrix. Piper Sandler & Co. is acting as the book-running manager and Craig-Hallum is acting as the lead manager for the offering.

Miromatrix Medical Inc. Announces Pricing of $10 Million Public Offering of Common Stock

EDEN PRAIRIE, Minn., March 07, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (“Miromatrix”) (Nasdaq: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that it has commenced an underwritten public offering of shares of its common stock. In connection with the offering, Miromatrix intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the offering at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are to be sold by Miromatrix. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Miromatrix Medical Inc. Announces Proposed Public Offering of Common Stock

NEW YORK , Feb. 6, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Miromatrix Medical Inc. ("Miromatrix" or the "Company") (NASDAQ: MIRO). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Miromatrix Medical Inc. - MIRO

Baxter

EDEN PRAIRIE, Minn. & DEERFIELD, Ill.--( BUSINESS WIRE )--Miromatrix Medical Inc. (NASDAQ: MIRO) and Baxter International Inc. (NYSE:BAX) today announced a collaborative research agreement to help support additional treatment options for patients with acute liver failure (ALF) in need of organ support therapies. As part of the collaboration, Miromatrix has created a new liver therapy called miroliverELAP that combines a Miromatrix single-use bioengineered liver with Baxter's PrisMax system. Miromatrix submitted an Investigational New Drug (IND) application for miroliverELAP to the U.S. Food and Drug Administration (FDA) in November 2022, which appears to be the first IND for a bioengineered organ. Miromatrix intends to commence a Phase I clinical trial using miroliverELAP to treat patients suffering from ALF, following FDA's decision that the trial may proceed. Baxter is both a collaborator and shareholder of Miromatrix.

Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure

EDEN PRAIRIE, Minn., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today provided a program update on miroliverELAP™.

News for Miromatrix Medical Inc Stock (MIRO)